In an update to clients Wednesday, Echelon Wealth Partners analyst Douglas Loe remains bullish on clinical stage drug developer Antibe Therapeutics … [Read more...] about Antibe Therapeutics has an upside of 352 per cent, Echelon Wealth says
ate
Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth
In a research update on Monday, Echelon Wealth Partners analyst Douglas Loe reiterated his “Speculative Buy” rating and $1.40 target price for … [Read more...] about Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth
Antibe Therapeutics has huge upside, Echelon Wealth says
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart TSXV:ATE) may keep trading sideways for a while yet but the drug developer’s ATB-346 … [Read more...] about Antibe Therapeutics has huge upside, Echelon Wealth says
Antibe Therapeutics has a 192 per cent upside, Echelon Wealth says
In a coverage launch on Thursday, Echelon Wealth Partners analyst Douglas Loe says clinical stage drug developer Antibe Therapeutics (TSXV:ATE) has … [Read more...] about Antibe Therapeutics has a 192 per cent upside, Echelon Wealth says
Antibe Therapeutics could shake up the NSAID market, says M Partners
Tiny Antibe Therapeutics (TSXV:ATE) may be set to shake up the massive NSAID market, says M Partners analyst Daniel Pearlstein. In a research report … [Read more...] about Antibe Therapeutics could shake up the NSAID market, says M Partners
